Phase 2 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Von Hippel-Lindau (VHL) disease, either through genetic testing that found a specific gene change, or through clinical diagnosis based on symptoms and medical history.
- People who have at least one sign of VHL affecting the pancreas (a gland in the abdomen), as seen on a scan or imaging test. This may include cysts on the pancreas, solid growths, tumours suspected to be a type called pancreatic neuroendocrine tumours (PNETs), or any other solid growths on the pancreas.
- People aged 12 years or older.
- People who are able to understand the study and are willing to sign a consent form agreeing to take part.
Who may not be able to join:
- People who are unable to have repeated non-invasive imaging scans (such as MRI or CT scans) over the course of the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Naris Nilubol, M.D., National Cancer Institute (NCI)
Phone: (240) 858-7033
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Characterization of the natural and clinical histories of VHL pancreatic neuroendocrine tumors and cystic lesions
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.